Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Vanda Pharmaceuticals's Revenue for the
three
months ended in Mar. 2026 was $51.7 Mil. Vanda Pharmaceuticals's average Accounts Receivable for the
three
months ended in Mar. 2026 was $55.7 Mil.
Hence, Vanda Pharmaceuticals's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.93.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Vanda Pharmaceuticals Receivables Turnover Related Terms
Vanda Pharmaceuticals Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Vanda Pharmaceuticals's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VNDA vs AVIR, OABI, TENX: Receivables Turnover Comparison
For the Biotechnology subindustry, Vanda Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanda Pharmaceuticals Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Vanda Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanda Pharmaceuticals (VNDA) has a Receivables Turnover of 0.93 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Vanda Pharmaceuticals and its competitors. According to the industry distribution chart, Vanda Pharmaceuticals ranks #502 out of 841 companies in the Biotechnology industry, placing it in the top 59.7%.
Is Vanda Pharmaceuticals' Receivables Turnover too high?
Vanda Pharmaceuticals' current Receivables Turnover is 0.93. The Biotechnology industry median Receivables Turnover is 5.29. Vanda Pharmaceuticals' value of 0.93 is 82.4% below this industry median. Based on the distribution chart, Vanda Pharmaceuticals ranks #502 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vanda Pharmaceuticals has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vanda Pharmaceuticals' Receivables Turnover compare to AVIR and OABI?
According to the Biotechnology industry distribution chart, Vanda Pharmaceuticals ranks #502 out of 841 companies for Receivables Turnover. This places Vanda Pharmaceuticals in the lower half of its industry. The industry median Receivables Turnover is 5.29. Vanda Pharmaceuticals' value of 0.93 is 82.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vanda Pharmaceuticals's current Receivables Turnover of 0.93 is 82.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Vanda Pharmaceuticals and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vanda Pharmaceuticals's current Receivables Turnover is 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vanda Pharmaceuticals (VNDA) is currently considered Fairly Valued. The stock's GF Value™ is $5.55, compared to a current price of $5.45 — trading 1.8% below its estimated fair value. The current Receivables Turnover is 0.93 and 82.4% below the Biotechnology industry median of 5.29. Vanda Pharmaceuticals' overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Vanda Pharmaceuticals (VNDA), the current Receivables Turnover is 0.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vanda Pharmaceuticals (VNDA) Overvalued in 2026?
Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be undervalued.
The current stock price of $5.45 is trading 1.8% below its estimated GF Value™ of $5.55.
GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.
Key valuation signals for VNDA:
Receivables Turnover: 0.93
GF Value™: $5.55 vs. price of $5.45 (1.8% below fair value)
Industry Position: 82.4% below the Biotechnology median (#502 of 841)
No single metric tells the full story. See the VNDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
74GF Score
Get the complete analysis for VNDA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VNDA has been successfully added to your 
